ASH 2020 | MURANO trial: duvelisib plus venetoclax in R/R CLL, SLL and Richter’s Syndrome
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the updated results from the MURANO trial (NCT03534323): a Phase I/II study aiming to evaluate the efficacy and safety of combined fixed-duration duvelisib and venetoclax treatment in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or Richter’s syndrome. This line of therapy was found to be generally well tolerated, with no dose-limiting toxicities or cases of tumor lysis syndrome being reported. Around 60% of the participants achieved a complete response and were able to discontinue treatment. These finding suggest that duvelisib and venetoclax may become a key approach in heavily pretreated populations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
